On March 12, 2026, the FDA sent a warning letter to Novo Nordisk for missing deadlines to report potential side effects of Ozempic and Wegovy. The letter referenced three patient deaths. Millions of people take these drugs, so the reaction has been understandably tense.
But the actual substance of this warning matters a lot more than the headlines.
What Happened
Drug companies are required to report adverse events to the FDA within strict timeframes. Novo Nordisk missed those deadlines for certain events tied to its GLP-1 medications. The warning letter is about that reporting failure -- it isn't flagging a new safety problem with the drugs themselves.
What the FDA Did Not Say
This part tends to get lost in the coverage:
- The FDA did not say Ozempic or Wegovy caused the deaths. Adverse event reports document things that happened while someone was on a medication. That's not the same as proving the medication caused them.
- The FDA did not recall or restrict either drug. Both remain fully approved and available.
- The FDA did not change its safety assessment. The known side effect profile of semaglutide hasn't changed because of this letter.
Should You Stop Taking Your Medication?
No -- don't stop any prescribed medication without talking to your doctor. This warning letter is a regulatory compliance issue between the FDA and a pharmaceutical company. It doesn't change the risk-benefit calculation that you and your provider made when you started treatment.
If you're feeling uneasy, call your prescribing provider. They can talk through your specific situation. Many clinics in our directory offer quick telehealth check-ins for existing patients.
What Novo Nordisk Must Do
The company has 15 business days to respond with a corrective action plan. Usually that means fixing their internal systems for tracking and reporting adverse events. The FDA will be watching.
Putting It in Context
FDA warning letters to drug companies aren't rare. The agency issued over 100 of them in 2025 alone, covering manufacturing problems, marketing violations, reporting delays, and more. A warning letter means there's a process problem -- not necessarily a product safety problem.
Semaglutide has been prescribed to tens of millions of patients worldwide since 2017 (for diabetes) and 2021 (for weight loss). Its safety record is one of the most studied of any weight loss drug, including large cardiovascular trials that showed reduced risk of heart attack and stroke.
What to Watch For
Regardless of this news, patients on GLP-1 medications should stay alert to the known side effects and tell their provider about anything concerning. That includes:
- Severe or persistent nausea, vomiting, or abdominal pain
- Signs of pancreatitis (severe abdominal pain radiating to the back)
- Changes in vision
- Symptoms of thyroid issues (lump or swelling in the neck, difficulty swallowing, hoarseness)
For a full rundown, see our guide to GLP-1 side effects.
Finding a Provider You Trust
If this has you rethinking your current provider, use our clinic search to find experienced GLP-1 clinics nearby. The ones worth your time offer thorough initial evaluations, regular follow-up visits, and straight talk about risks -- our guide on finding the best GLP-1 clinic near you covers what to look for.
This article is for informational purposes only and does not constitute medical advice. Do not make changes to your medication regimen without consulting your healthcare provider.